| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
46,860 |
35,416 |
$2.54M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
21,903 |
17,001 |
$1.42M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
8,260 |
6,341 |
$850K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
8,844 |
7,174 |
$575K |
| 99199 |
Unlisted special service, procedure or report |
54,971 |
31,361 |
$410K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,717 |
6,851 |
$330K |
| 83970 |
|
3,569 |
2,916 |
$149K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
3,623 |
2,960 |
$108K |
| 99406 |
|
12,852 |
9,273 |
$93K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
7,001 |
4,022 |
$80K |
| 81025 |
|
7,735 |
5,789 |
$47K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
391 |
308 |
$41K |
| 84480 |
|
2,472 |
2,009 |
$35K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
532 |
422 |
$34K |
| 80061 |
Lipid panel |
2,403 |
1,970 |
$31K |
| 86769 |
|
783 |
628 |
$27K |
| 80053 |
Comprehensive metabolic panel |
3,194 |
2,675 |
$27K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,297 |
2,753 |
$26K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
377 |
293 |
$25K |
| 90791 |
Psychiatric diagnostic evaluation |
376 |
285 |
$25K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,176 |
2,571 |
$25K |
| 93000 |
|
2,361 |
1,935 |
$23K |
| 84439 |
|
2,475 |
2,021 |
$22K |
| 94375 |
|
1,192 |
936 |
$21K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
281 |
210 |
$20K |
| 72100 |
|
1,392 |
1,134 |
$20K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,127 |
968 |
$18K |
| 36415 |
Collection of venous blood by venipuncture |
9,877 |
7,795 |
$16K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
76 |
49 |
$14K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
501 |
360 |
$13K |
| 72050 |
|
698 |
556 |
$13K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
271 |
226 |
$13K |
| 86803 |
|
972 |
769 |
$12K |
| 82607 |
|
796 |
595 |
$11K |
| 82962 |
|
7,425 |
5,813 |
$10K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
152 |
114 |
$9K |
| 99442 |
|
292 |
178 |
$9K |
| 99215 |
Prolong outpt/office vis |
130 |
103 |
$9K |
| 82746 |
|
613 |
490 |
$9K |
| 82728 |
|
661 |
527 |
$9K |
| 87340 |
|
917 |
740 |
$8K |
| 83735 |
|
1,066 |
830 |
$7K |
| 80050 |
General health panel |
783 |
667 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
483 |
384 |
$7K |
| 72070 |
|
542 |
443 |
$7K |
| 99443 |
|
107 |
67 |
$6K |
| 83550 |
|
660 |
527 |
$6K |
| 86703 |
|
427 |
353 |
$5K |
| 99401 |
|
220 |
156 |
$4K |
| 81002 |
|
2,908 |
2,141 |
$4K |
| 83880 |
|
103 |
84 |
$4K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
41 |
26 |
$3K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
19 |
16 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
151 |
114 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
74 |
64 |
$3K |
| 99385 |
|
32 |
27 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,230 |
2,347 |
$3K |
| 83540 |
|
378 |
292 |
$2K |
| 90756 |
|
257 |
216 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
434 |
351 |
$2K |
| 84550 |
|
512 |
433 |
$2K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
39 |
27 |
$2K |
| 93248 |
|
171 |
157 |
$2K |
| 86431 |
|
465 |
391 |
$2K |
| 93246 |
|
190 |
172 |
$2K |
| 72080 |
|
127 |
99 |
$1K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
645 |
540 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,318 |
2,500 |
$1K |
| 86141 |
|
80 |
70 |
$1K |
| 99407 |
|
62 |
50 |
$996.04 |
| 93015 |
|
34 |
27 |
$841.35 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
15 |
12 |
$762.44 |
| 90688 |
|
119 |
81 |
$749.70 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
67 |
59 |
$722.36 |
| 94618 |
|
39 |
32 |
$545.41 |
| 82044 |
|
329 |
269 |
$516.35 |
| 3044F |
|
5,459 |
4,445 |
$480.00 |
| 96146 |
|
394 |
310 |
$250.09 |
| 95117 |
|
45 |
12 |
$236.60 |
| 90661 |
|
53 |
43 |
$228.55 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
522 |
466 |
$215.47 |
| 82150 |
|
32 |
27 |
$207.68 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
77 |
62 |
$183.48 |
| 3074F |
|
13,747 |
11,097 |
$100.00 |
| 83690 |
|
30 |
25 |
$98.85 |
| 3078F |
|
13,246 |
10,903 |
$75.00 |
| 80320 |
|
248 |
223 |
$67.26 |
| 90834 |
Psychotherapy, 45 minutes with patient |
42 |
32 |
$50.43 |
| 96160 |
|
112 |
92 |
$38.50 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
189 |
144 |
$34.14 |
| 3079F |
|
7,532 |
6,245 |
$25.00 |
| 3075F |
|
3,664 |
3,135 |
$0.01 |
| 3080F |
|
1,351 |
1,101 |
$0.01 |
| 1125F |
|
2,172 |
1,754 |
$0.01 |
| 1170F |
|
205 |
186 |
$0.00 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
639 |
549 |
$0.00 |
| 3048F |
|
1,491 |
1,194 |
$0.00 |
| 3008F |
|
22,552 |
18,071 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
34 |
27 |
$0.00 |
| 3049F |
|
854 |
684 |
$0.00 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
340 |
258 |
$0.00 |
| H0025 |
Behavioral health prevention education service (delivery of services with target population to affect knowledge, attitude and/or behavior) |
155 |
105 |
$0.00 |
| 4010F |
|
84 |
73 |
$0.00 |
| 3288F |
|
3,557 |
2,892 |
$0.00 |
| 4004F |
|
4,739 |
3,618 |
$0.00 |
| 3077F |
|
3,216 |
2,700 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
1,867 |
1,444 |
$0.00 |
| G0446 |
Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes |
534 |
479 |
$0.00 |
| 4013F |
|
234 |
176 |
$0.00 |
| 3050F |
|
467 |
361 |
$0.00 |
| 98960 |
|
104 |
77 |
$0.00 |
| 4019F |
|
76 |
60 |
$0.00 |
| 1159F |
|
197 |
182 |
$0.00 |
| 3051F |
|
212 |
181 |
$0.00 |
| 3046F |
|
188 |
158 |
$0.00 |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
15 |
15 |
$0.00 |